Skip to main content
. 2018 Sep 26;14:1789–1797. doi: 10.2147/TCRM.S176214

Figure 4.

Figure 4

The pooled OR of secondary outcomes for the comparison of the concurrent vs nonconcurrent use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.

Abbreviations: HER2, human epidermal growth factor receptor 2; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response.